The cholinergic hypothesis of Alzheimer's disease: a review of progress.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Use of Drugs Affecting GABAMolecular neurobiology · 2025
   Pooled it
2. The cellular model for Alzheimer's disease research: PC12 cells.Frontiers in molecular neuroscience · 2022
   Pooled it
3. Plant-mediated green nanoparticles: combining nanometal and biometabolite potential for Alzheimer's treatment.Biomedical engineering online · 2026
   Review
4. Amyloid Beta in Alzheimer's Disease: Mechanisms, Biomarker Potential, and Therapeutic Targets.CNS neuroscience & therapeutics · 2025
   Review
5. Preclinical Alzheimer's disease shows alterations in circulating neuronal-derived extracellular vesicle microRNAs in a multiethnic cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
   Article
6. Microbial Trojan Horses: Virulence Factors as Key Players in Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2025
   Review
7. Evolution of Alzheimer's Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy.Pharmaceutics · 2025
   Review
8. Alzheimer's disease: from early pathogenesis to novel therapeutic approaches.Metabolic brain disease · 2024
   Review
9. Cognitive synaptopathy: synaptic and dendritic spine dysfunction in age-related cognitive disorders.Frontiers in aging neuroscience · 2024
   Review
10. Therapeutic Strategies Aimed at Improving Neuroplasticity in Alzheimer Disease.Pharmaceutics · 2023
    Review
11. Using Optogenetics to Model Cellular Effects of Alzheimer's Disease.International journal of molecular sciences · 2023
    Review
12. Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.Pharmacology & therapeutics · 2022
    Review
13. Adult hippocampal neurogenesis and its impairment in Alzheimer's disease.Zoological research · 2022
    Review
14. Neuroprotective Effects and Mechanisms of Senegenin, an Effective Compound Originated From the Roots of Polygala Tenuifolia.Frontiers in pharmacology · 2022
    Review
15. Naringin Exhibits Mas Receptor-Mediated Neuroprotection Against Amyloid Beta-Induced Cognitive Deficits and Mitochondrial Toxicity in Rat Brain.Neurotoxicity research · 2021
    Article
16. Comprehensive Review on Alzheimer's Disease: Causes and Treatment.Molecules (Basel, Switzerland) · 2020
    Review
17. Neurovascular Unit Dysfunction and Neurodegenerative Disorders.Frontiers in neuroscience · 2020
    Review
18. A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.CNS drugs · 2019
    Review
19. Identification of novel acetylcholinesterase inhibitors designed by pharmacophore-based virtual screening, molecular docking and bioassay.Scientific reports · 2018
    Article
20. Functional MRI technologies in the study of medication treatment effect on Alzheimer's disease.Aging medicine (Milton (N.S.W)) · 2018
    Review

Corrections and comments

• Comment on
  The cholinergic hypothesis of Alzheimer's disease: a review of progress.1999

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as